ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO was delisted on the 27th of March, 2020.
0 hedge funds and large institutions have $0 invested in ProShares UltraPro Short NASDAQ Biotechnology in 2020 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $9K → $0 (-$9K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplex Trading
Chicago,
Illinois
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Simplex Trading
Chicago,
Illinois
| – | -$9K | -1,026 | Closed |
|
ZBIO Hedge Fund Activity: Q2 2020 in Review
0 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q2 2020, worth a combined $0 — down 100% from $9K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ZBIO and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Simplex Trading, exiting entirely with an estimated $9K sold.
- 0 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q2 2020, down from 1 in Q1 2020.
- Funds reported $0 of ProShares UltraPro Short NASDAQ Biotechnology stock for Q2 2020, down 100% quarter-over-quarter.
- 0 funds opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q2 2020 and 1 closed out, a net change of -1 holder.
- The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q2 2020 was Simplex Trading, an estimated $9K sold.
Based on aggregated 13F filings for Q2 2020.